MA49564A - Modulateurs thérapeutiques du mode inverse de l'atp synthase - Google Patents

Modulateurs thérapeutiques du mode inverse de l'atp synthase

Info

Publication number
MA49564A
MA49564A MA049564A MA49564A MA49564A MA 49564 A MA49564 A MA 49564A MA 049564 A MA049564 A MA 049564A MA 49564 A MA49564 A MA 49564A MA 49564 A MA49564 A MA 49564A
Authority
MA
Morocco
Prior art keywords
reverse
atp synthase
therapeutic modulators
mode therapeutic
mode
Prior art date
Application number
MA049564A
Other languages
English (en)
Inventor
Michael David Forrest
Original Assignee
Michael David Forrest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1711250.9A external-priority patent/GB201711250D0/en
Priority claimed from GBGB1715756.1A external-priority patent/GB201715756D0/en
Priority claimed from GBGB1715758.7A external-priority patent/GB201715758D0/en
Priority claimed from GBGB1715938.5A external-priority patent/GB201715938D0/en
Priority claimed from GBGB1716492.2A external-priority patent/GB201716492D0/en
Priority claimed from GBGB1800092.7A external-priority patent/GB201800092D0/en
Priority claimed from GBGB1800291.5A external-priority patent/GB201800291D0/en
Priority claimed from GBGB1800581.9A external-priority patent/GB201800581D0/en
Priority claimed from PCT/EP2018/051127 external-priority patent/WO2018134265A1/fr
Priority claimed from GBGB1801536.2A external-priority patent/GB201801536D0/en
Priority claimed from GBGB1806421.2A external-priority patent/GB201806421D0/en
Priority claimed from GBGB1808331.1A external-priority patent/GB201808331D0/en
Priority claimed from GBGB1809497.9A external-priority patent/GB201809497D0/en
Priority claimed from GBGB1810236.8A external-priority patent/GB201810236D0/en
Priority claimed from GBGB1811188.0A external-priority patent/GB201811188D0/en
Application filed by Michael David Forrest filed Critical Michael David Forrest
Publication of MA49564A publication Critical patent/MA49564A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA049564A 2017-07-13 2018-07-13 Modulateurs thérapeutiques du mode inverse de l'atp synthase MA49564A (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GBGB1711250.9A GB201711250D0 (en) 2017-07-13 2017-07-13 Cancer therapy
GBGB1715756.1A GB201715756D0 (en) 2017-09-28 2017-09-28 Disclosure
GBGB1715758.7A GB201715758D0 (en) 2017-09-28 2017-09-28 Disclosing
GBGB1715938.5A GB201715938D0 (en) 2017-10-01 2017-10-01 Disclosure
GBGB1716492.2A GB201716492D0 (en) 2017-10-09 2017-10-09 Disclosure
GBGB1800092.7A GB201800092D0 (en) 2018-01-04 2018-01-04 Disclosure
GBGB1800291.5A GB201800291D0 (en) 2018-01-08 2018-01-08 Disclosure
GBGB1800581.9A GB201800581D0 (en) 2018-01-15 2018-01-15 Disclosure
PCT/EP2018/051127 WO2018134265A1 (fr) 2017-01-17 2018-01-17 Inhibiteurs thérapeutiques du mode inverse de l'atp synthase
GBGB1801536.2A GB201801536D0 (en) 2018-01-30 2018-01-30 Disclosure
GBGB1806421.2A GB201806421D0 (en) 2018-04-19 2018-04-19 Disclosure
GBGB1808331.1A GB201808331D0 (en) 2018-05-21 2018-05-21 Disclosure
GBGB1809497.9A GB201809497D0 (en) 2018-06-08 2018-06-08 Disclosure
GBGB1810236.8A GB201810236D0 (en) 2018-06-21 2018-06-21 Disclosure
GBGB1811188.0A GB201811188D0 (en) 2018-07-08 2018-07-08 Disclosure

Publications (1)

Publication Number Publication Date
MA49564A true MA49564A (fr) 2021-04-28

Family

ID=65001115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049564A MA49564A (fr) 2017-07-13 2018-07-13 Modulateurs thérapeutiques du mode inverse de l'atp synthase

Country Status (14)

Country Link
US (2) US12337000B2 (fr)
EP (1) EP3652156A1 (fr)
JP (2) JP2021510365A (fr)
CN (2) CN111278810A (fr)
AU (3) AU2018298892B2 (fr)
BR (1) BR112019028172A2 (fr)
CA (1) CA3099077A1 (fr)
CO (1) CO2020001107A2 (fr)
IL (1) IL271845B2 (fr)
MA (1) MA49564A (fr)
PH (1) PH12020551543A1 (fr)
RU (1) RU2020105742A (fr)
SG (1) SG11202000331YA (fr)
WO (1) WO2019012149A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
WO2021186325A1 (fr) * 2020-03-15 2021-09-23 Forrest Michael David Almitrines pour le traitement de l'hypoxémie d'une infection par coronavirus
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
WO2022157548A1 (fr) 2021-01-24 2022-07-28 Forrest Michael David Inhibiteurs d'utilisations cosmétiques et thérapeutiques d'atp synthase
WO2023047151A1 (fr) 2021-09-22 2023-03-30 Forrest Michael David Biomarqueurs du cancer pour la susceptibilité au traitement par almitrine
JP2025019826A (ja) 2023-07-28 2025-02-07 株式会社アルファ リッド装置
WO2025240818A1 (fr) * 2024-05-16 2025-11-20 Oregon Health & Science University Agonistes de l'adn glycosylase 8-oxo-guanine

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US436494A (en) 1890-09-16 Furnace
US522540A (en) 1894-07-03 Locomotive ash-pan
GB1256513A (fr) 1968-10-02 1971-12-08
FR2488509A1 (fr) * 1980-08-18 1982-02-19 Science Union & Cie Nouvelles compositions pharmaceutiques contenant de l'almitrine
FR2521560A1 (fr) 1982-02-17 1983-08-19 Adir Nouveaux derives de piperazine et d'homopiperazine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FR2524467A1 (fr) 1982-03-30 1983-10-07 Adir Polymethylene-imines disubstituees, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FR2525597B1 (fr) 1982-04-21 1985-06-07 Adir Polymethylene diamines n,n'-substituees, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
FR2544315B1 (fr) 1983-04-12 1985-07-05 Adir Polymethylene imines disubstituees, leurs procedes de preparation, et les compositions pharmaceutiques les renfermant
BR8806902A (pt) 1987-04-16 1989-10-31 Christian Bindschaedler Processo para preparacao de um po de polimero insoluvel em agua que pode ser redispersado em uma fase liquida,po resultante e sua utilizacao
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
FR2667243B1 (fr) * 1990-09-27 1994-11-04 Adir Utilisation de s derives de la triazine et de la pyrimidine pour l'obtention de medicaments reversant la resistance aux agents anticancereux et antimalariques.
JP3523252B2 (ja) 1990-11-21 2004-04-26 ホウテン ファーマシューティカルズ インコーポレイテッド 等モル多種オリゴマー混合物、特にオリゴペプチド混合物の合成
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5869478A (en) 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
EP0920445B1 (fr) 1996-08-23 2003-01-02 Sederma S.A. Peptides synthetiques et leur utilisation dans les compositions cosmetiques ou dermopharmaceutiques
GB9714680D0 (en) 1997-07-11 1997-09-17 Medical Res Council Recombinant production of proteins
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
FR2783169B1 (fr) 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040072739A1 (en) 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
US20030026781A1 (en) 1999-11-10 2003-02-06 Mitokor Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
SE0002232D0 (sv) 2000-06-15 2000-06-15 Vulpes Ltd Antioxidant
AU2002306500C1 (en) 2001-02-16 2006-09-28 Cellgate, Inc. Transporters comprising spaced arginine moieties
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
FR2830195B1 (fr) 2001-10-03 2004-10-22 Sederma Sa Compositions cosmetiques et dermopharmaceutiques pour les peaux a tendance acneique
ATE510852T1 (de) 2001-10-30 2011-06-15 Dsm Ip Assets Bv Dermopharmazeutisch und kosmetisch wirksame oligopeptide
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2002357137A1 (en) 2001-12-10 2003-06-23 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
FR2836042B1 (fr) 2002-02-15 2004-04-02 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux
WO2003089456A2 (fr) 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs peptidiques de la proteine kinase c
US20040009972A1 (en) 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
ES2280962T3 (es) 2003-05-08 2007-09-16 Pentapharm Ag Tripeptidos y derivados de los mismos para aplicaciones cosmeticas para la estructura de la piel.
US7208595B2 (en) 2003-07-25 2007-04-24 The Ohio State University Research Foundation Peptide deformylase inhibitors as novel antibiotics
WO2011008992A2 (fr) 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides dont l’absorption par les cellules peut être régulée
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2005048968A1 (fr) 2003-11-17 2005-06-02 Sederma Compositions contenant des melanges de tetrapeptides et de tripeptides
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
WO2007035474A2 (fr) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Peptides d'administration transdermique et procede d'utilisation de ceux-ci
EP1984387B1 (fr) 2006-02-16 2017-05-31 Sederma Polypeptides kxk et leurs applications
ATE495197T1 (de) 2006-03-20 2011-01-15 Cepep Iii Ab Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel
EP1998809B1 (fr) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Conjugués de camptothecin et peptide pénétrant la cellule et composition pharmaceutique les contenant.
JP2010514779A (ja) 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． 逆配列ｈｉｖ−ｔａｔポリペプチドを用いる輸送分子
WO2008089491A2 (fr) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications de compositions peptidiques pour augmenter la stabilité et l'efficacité d'administration
CA2688240A1 (fr) 2007-05-24 2008-12-04 The United States Government As Represented By The Department Of Veterans Affairs Transduction de proteines intranucleaires par voie de recuperation des nucleosides
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
WO2009102707A2 (fr) 2008-02-11 2009-08-20 Auspex Pharmaceuticals, Inc. Oxazaphosphorines substituées
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
CN102811744A (zh) 2008-09-16 2012-12-05 卡里姆·阿梅德 用于改善基因调节化合物的递送的化学修饰的细胞渗透性肽
WO2010111533A2 (fr) 2009-03-25 2010-09-30 Kai Pharmaceuticals, Inc. Administration transdermique de peptides modulateurs de la pkc à travers une zone de peau rendue microporeuse
JP5782439B2 (ja) 2009-07-24 2015-09-24 リポテック, エセ.ア.Lipotec, S.A. 筋肉収縮を抑制する化合物
WO2011085000A2 (fr) 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Dérivés d'acides gras et analogues de médicaments
EP2576595B1 (fr) 2010-05-30 2016-12-21 The Governing Council Of The University Of Toronto Peptides pénétrant dans les mitochondries comme vecteurs de composés anticancéreux
US20130078295A1 (en) 2010-06-09 2013-03-28 Lipotec S.A. Skin antiaging treatment
CA2811113A1 (fr) 2010-11-09 2012-05-18 The Regents Of The University Of California Peptides entrant dans les cellules et traversant la peau (space) et leurs procedes d'utilisation
SG10201601507YA (en) 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
CA2836299A1 (fr) 2011-04-15 2012-10-18 Genelux Corporation Souches clonales de virus attenues de la vaccine et leurs procedes d'utilisation
US9333152B2 (en) 2011-11-04 2016-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
CN104105499A (zh) 2011-12-09 2014-10-15 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
US9580391B2 (en) 2012-06-08 2017-02-28 Lycera Corporation Saturated acyl guanidine for inhibition of F1F0-ATPase
FR2998570B1 (fr) 2012-11-26 2016-12-02 Sederma Sa Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
WO2014123543A2 (fr) 2013-02-11 2014-08-14 Convoy Therapeutics Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation
US20140227174A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use therefor
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
US10577303B1 (en) 2013-03-14 2020-03-03 Wisconsin Alumni Research Foundation Reagents and methods for esterification
EP2792684A1 (fr) 2013-04-15 2014-10-22 Lipotec, S.A. Composés utiles dans le traitement et/ou le soin de la peau et leurs compositions cosmétiques ou pharmaceutiques
US10287331B2 (en) 2013-04-15 2019-05-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Mitochondrial proteins constructs and uses thereof
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
WO2014210056A1 (fr) 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Agents thérapeutiques peptidiques, et leurs procédés d'utilisation
GB2516045A (en) 2013-07-09 2015-01-14 Neuro Bio Ltd Neurodegenerative disorders
CN105491982B (zh) 2013-08-12 2019-09-10 3M创新有限公司 用于增强透皮递送的肽
US10736932B2 (en) 2014-05-20 2020-08-11 Ohio State Innovation Foundation Small molecule Ras inhibitors
RS59119B1 (sr) 2014-05-21 2019-09-30 Entrada Therapeutics Inc Peptidi koji prodiru u ćelije i postupci za njihovo pravljenje i upotrebu
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
FR3021319B1 (fr) 2014-05-22 2018-08-31 Sederma Peptides, compositions les comprenant et utilisations notamment cosmetiques
US20170258930A1 (en) 2014-08-27 2017-09-14 The Regents Of The University Of California Skin penetrating peptides (spps) and methods of use therefor
US10258695B2 (en) 2014-09-04 2019-04-16 Wisconsin Alumni Research Foundation Protein derivatization to endow cell penetration
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
RS61853B1 (sr) 2014-10-29 2021-06-30 Bicyclerd Ltd Biciklični peptidni ligandi specifični za mt1-mmp
GB2539161A (en) 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
FR3029782B1 (fr) 2014-12-16 2019-06-07 Sederma Composes peptidiques, compositions les comprenant et utilisations notamment cosmetiques
CA2974623A1 (fr) 2015-01-23 2016-07-28 Erasmus University Medical Center Rotterdam Composes anti-senescence et leurs utilisations
US9790483B2 (en) 2015-04-09 2017-10-17 Wisconsin Alumni Research Foundation Reagents and methods for esterification
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
US20180251495A1 (en) 2015-09-15 2018-09-06 The Regents Of The University Of California Skin-Penetrating Peptides and Compositions and Methods of Use Thereof
CN105693806A (zh) * 2016-04-23 2016-06-22 何华琼 一种二甲磺酸阿米三嗪的药物组合物及其医药用途
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
CN110114075B (zh) 2016-11-09 2024-01-12 俄亥俄州国家创新基金会 含有二硫化物的细胞穿透肽及其制备和使用方法
US10913773B2 (en) 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2018127699A1 (fr) 2017-01-06 2018-07-12 Bicyclerd Limited Composés permettant de traiter le cancer
US12410143B2 (en) 2017-01-17 2025-09-09 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
EP3630089A4 (fr) * 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. Méthodes de traitement du cancer
US20220273664A1 (en) 2017-06-23 2022-09-01 The Governing Council Of The University Of Toronto Mitochondrial Targeted Releasable Linker
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
CA3078504A1 (fr) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Inhibiteurs peptidiques bicycliques
WO2019148194A2 (fr) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Inhibiteurs peptidyliques de l'interaction calcineurine-nfat
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
FR3077202B1 (fr) 2018-02-01 2020-01-10 Sederma Utilisation de cyclopeptides en cosmetique
WO2019199841A1 (fr) 2018-04-09 2019-10-17 Cure Ahc, Inc. Administration médiée par aav de gènes atp1a3 au système nerveux central
WO2021016330A2 (fr) 2019-07-22 2021-01-28 Oneskin, Inc. Polypeptides ayant des effets anti-sénescence et leurs utilisations
CA3050553A1 (fr) 2019-07-25 2021-01-25 Michael D. Forrest Modificateurs therapeutiques du mode inverse de l`atp-synthase
AU2019208238A1 (en) 2019-07-26 2021-02-11 Forrest, Michael David DR Therapeutic Modifiers of the Reverse Mode of ATP Synthase
WO2021186325A1 (fr) 2020-03-15 2021-09-23 Forrest Michael David Almitrines pour le traitement de l'hypoxémie d'une infection par coronavirus

Also Published As

Publication number Publication date
AU2024200288B2 (en) 2026-02-05
IL271845A (en) 2020-02-27
CO2020001107A2 (es) 2020-05-15
US12337000B2 (en) 2025-06-24
CN111278810A (zh) 2020-06-12
AU2018298892A1 (en) 2020-02-20
JP2021510365A (ja) 2021-04-22
RU2020105742A (ru) 2021-08-13
CA3099077A1 (fr) 2019-01-17
US20200306253A1 (en) 2020-10-01
EP3652156A1 (fr) 2020-05-20
BR112019028172A2 (pt) 2020-10-06
JP2023123664A (ja) 2023-09-05
PH12020551543A1 (en) 2020-10-26
AU2018298892B2 (en) 2022-06-23
AU2024200288A1 (en) 2024-02-08
CN118652215A (zh) 2024-09-17
IL271845B1 (en) 2024-02-01
WO2019012149A1 (fr) 2019-01-17
SG11202000331YA (en) 2020-02-27
US20250057851A1 (en) 2025-02-20
AU2022235526A1 (en) 2022-10-13
IL271845B2 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
MA49564A (fr) Modulateurs thérapeutiques du mode inverse de l'atp synthase
ZA201908496B (en) Small molecule modulators of human sting
EP3353328A4 (fr) Modulateurs de l'expression de kras
EP3645100C0 (fr) Compensation d'insertion d'instrument
EP3349761A4 (fr) Modulateurs des protéines du noyau de l'hépatite b
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
EP3325963A4 (fr) Amélioration de l'estimation de globules
EP3474846A4 (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA46180A (fr) Analogues de l'amyline
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
MA43756A (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
FI20165061L (fi) Aluksen itsenäinen käyttö
EP3250367A4 (fr) Étalonnage d'agent
EP3733242C0 (fr) L'assurance qualité de radiothérapie
EP3314503A4 (fr) Simulation d'une application
GB201709959D0 (en) Small molecule modulators of human STING
MA44253A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
MA50435A (fr) Anticorps anti-ligand anti-cd40 thérapeutiques
EP3531991C0 (fr) Système d'hyperthermie de la totalité du corps
EP3573044A4 (fr) Corps d'affichage
EP3558946A4 (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
ITUA20161599A1 (it) Contenitore e procedimento per la realizzazione dello stesso
EP3544961A4 (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4